Adaptive designs in clinical drug development: Opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 6, 2007, Pages 957-964

  Krams, Michael ^a   Burman, Carl Fredrik ^b   Dragalin, Vladimir ^a   Gaydos, Brenda ^c   Grieve, Andrew P ^d   Pinheiro, Jose ^e   Maurer, Willi ^e  

^a PFIZER INC   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adaptive design; Clinical trial; Drug development

Indexed keywords

CONFERENCE PAPER; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; LEARNING; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; HUMANS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36249017451     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701643764     Document Type: Conference Paper

References (22)

1. Bauer, P., Kohne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029-1041.
2. Bornkamp, B., et al. (2007). White paper of the PhRMA PISC working group on adaptive dose-ranging designs. J. Bioph. Stat. 17.
3. Burman, C.-F., Senn, S. (2003). Examples of option values in drug development. Pharm. Stat. 2:113-125.
4. Chuang-Stein, C., Anderson, K., Gallo, P., Collins, S. (2006). Sample size reestimation: a review and recommendations. Drug Info. J. 40:475-484.
5. Dragalin, V. (2006). Terminology and classification of adaptive designs. Drug Info. J. 40:425-435.
6. ESG (2006). Expert Scientific Group on Phase I Clinical Trials: Final Report (page 103, points 14-16). London: Department of Health.
7. Gallo, P. (2006). Confidentiality and trial integrity issues for adaptive designs. Drug Info. J. 40:445-450.
8. Gallo, P., Krams, M. (2006). PhRMA working group on adaptive designs: Introduction to the full white paper. Drug Info. J. 40:421-423.
9. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. (2006). Executive summary of the PhRMA working group on adaptive designs in clinical drug development. J Biopharm. Stat. 16:275-283.
10. Gaydos, B., Krams, M., Perevozskaya, I., Bretz, F., Liu, Q., Gallo, P., Berry, D. A., Chuang-Stein, C., Pinheiro, J., Bedding, A. (2006). Adaptive dose-response studies. Drug Info. J. 40:451-461.
11. Gombar, C., Loh, E. (2007). Learn & Confirm. A new approach to drug development at Wyeth. Drug Discov. Dev. 10:22-27.
12. Jennison, C., Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Boca Raton, Florida: Chapman & Hall.
13. Kieser, M., Friede, T. (2003). Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat. Med. 22:3571-3581.
14. Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P., Krams, M. (2006). Adaptive seamless phase II/III designs - background, operational aspects, and examples. Drug Info. J. 4:463-473.
15. PhRMA (2006). Slide presentations given at November's workshop on adaptive designs are available at www.innovation.org/index.cfm/NewsCenter/ Briefings/Adaptive_Designs_Workshop.
16. Quinlan, J. A., Krams, M. (2006). Implementing adaptive designs: Logistical and operational considerations. Drug Info. J. 40:437-444.
17. Rosenberger, W. F. (1999). Randomized play-the-winner clinical trials: Review and recommendations. Contr. Clin. Trials 20:328-342.
18. Senn, S. (2004). Added values - Controversies concerning randomization and additivity in clinical trials. Stat. Med. 23:3729-3753.
19. Sheiner, L. B. (1997). Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61:275-291.
20. Taves, D. R. (1974). Minimization: a new method of assigning patients to treatment and control groups. Clin. Pharmacol. Ther. 15:443-453.
21. Whitehead, J. (1997). The Design and Analysis of Sequential Clinical Trials. 2nd ed. Chichester: Wiley.
22. Zelen, M. (1969). Play the winner rule and the controlled clinical trial. JASA 64:131-146.